GLP-1 receptor agonists show potential in reducing obesity-associated cancers among type 2 diabetes patients: JAMA
USA: The cohort study of more than 1.6 million patients with type 2 diabetes (T2D) with no prior diagnosis of 13 obesity-associated cancers (OACs) showed that glucagon-like peptide receptor agonists (GLP-1RAs) may reduce the risk of specific compared with …